Neoadjuvant TCHP Versus THP in Patients With HER2-positive Breast Cancer (neoCARHP Study)

NCT04858529 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

774

Enrollment

OTHER

Sponsor class

Conditions

Neoadjuvant Therapies for HER2+ Breast Cancer

Interventions

DRUG: investigator-selected taxane/carboplatin/trastuzumab/pertuzumab (TCHP)
DRUG: investigator-selected taxane/trastuzumab/pertuzumab (THP)

Sponsor

Guangdong Provincial People's Hospital